Eight months after striking a $335 million partnership deal, startup CRISPR Therapeutics and Germany's Bayer AG are taking the wraps off the new company formed to develop drugs using CRISPR's gene editing technology. The partners are set to announce Friday that they have christened the joint venture Casebia Therapeutics, and plan to move the company early next year into new offices and labs at 610 Main St. in Cambridge, subleasing 33,000 square feet of space at a Pfizer Inc. research complex outside Kendall Square.